/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

Investment provides Hydreight early exposure to emerging peptide delivery technologies while reinforcing its role as a national healthcare infrastructure platform supporting the rapidly expanding global peptide therapeutics market.

VANCOUVER, BC, March 13, 2026 /CNW/ – Hydreight Technologies Inc. (TSXV: NURS) (OTC: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a national digital healthcare infrastructure platform operating across the United States, today announced the closing of a $300,000 strategic investment in Insu Therapeutics Inc. (“Insu”) through the acquisition…